Exhibit 10.55
March 6, 2006
Dr. Nicholas A
Saccamano,
Senior Vice President,
Global Research
Technology,
Pfizer Inc.,
50 Pequot Avenue,
New London, CT 06320
RE: Third Amending Letter of
Agreement between Pfizer Inc. and Immunicon Corporation
Dear Dr Saccamano:
Immunicon Corporation
(“Immunicon”) wishes to amend the agreement between
Pfizer Inc. and its Affiliates (“Pfizer”) and
Immunicon, executed on February 10, 2003 having a termination
date of February 10, 2004, whi